| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: present invention refers to application in an effective amount and to new nicotine receptor agonists described by general formula (i) or (ii) for treating inflammatory diseases chosen from a group including asthma, chronic obstructive pulmonary disease (COPD), interstitial pulmonary tissue fibrosis (IPF), sarcoidosis, hypersensitivity pneumonitis (HP), chronic hypersensitivity pneumonitis and bronchiolitis obliterans organising pneumonia (BOOP). The compounds (i) and compounds (ii) relate to formulae (i) (ii) where in formula (i) R 1 and R 2 independently mean alkyl with 1-10 carbon atoms; Xa means CH or N; Ya means one or more substitutes chosen from hydrogen, halogen, cyano, hydroxyl, alkyl with 1-10 carbon atoms optionally substituted with one or more halogen atoms, and alkoxy with 1-10 carbon atoms; n means an integer 0 or 2; J means a counterion representing a compound for maintaining electric neutrality, e.g., halogen, sulphate, sulphonate; in formula (ii) R 3 is chosen from or Xb means N or N + -R 10 ; R 4 means one or more substitutes chosen from hydrogen, halogen; each R 10 , R 11 and R 12 independently means alkyl with 1-10 carbon atoms; provided the presence of the counterion when Xb means N + -R 10 . n EFFECT: use of nicotine receptor agonists in the effective amount for treating inflammatory diseases. n 26 cl, 40 dwg, 3 tbl, 38 ex |